Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Eligible patients will be women with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have completed standard therapy for primary or recurrent disease (i.e., patients who would normally be observed); eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen 125 (CA-125); or may be in complete clinical remission after treatment for primary or recurrent disease; these patients would normally enter a period of observation after standard management

Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)

Tumor expression of NY-ESO-1 or cancer/testis antigen 2 (LAGE-1) by immunohistochemistry (IHC) and/or real-time polymerase chain reaction (RT-PCR)

No allergy to eggs

Life expectancy \> 6 months

Hematology and biochemistry laboratory results within the limits normally expected for the patient population, without evidence of major organ failure

Absolute neutrophil count (ANC) \>= 1,000/uL

Platelet \>= 75,000/uL

Hemoglobin (Hgb) \>= 8 g/dL

Total bilirubin =\< 1.5 x upper limit of normal (ULN)

Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) =\< 3 x ULN

Serum creatinine =\< 2 x ULN

Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5

Electrocardiogram, showing no evidence of congestive heart failure, myocardial infarction, and cardiomyopathy

Have been informed of other treatment options

Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =\< 2

Demonstrate the ability to swallow and retain oral medication

Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment

Patients may have received previous NY-ESO-1 vaccine therapy

What this study is about